Butterfly Network’s Large Shift From Ultrasound Devices To Licensing

and software program, whereas nonetheless promoting {hardware} and subscriptions.

On positioning: Butterfly sits the place medical imaging, point-of-care units, and imaging software program/AI overlap. It competes with legacy cart-based ultrasound leaders (GE, Philips, Canon/Canon Medical, Siemens Healthineers) and newer handheld/moveable gamers (Clarius, Fujifilm SonoSite, and others). Butterfly’s moat case is “technology + ecosystem”: its chip-based method can decrease {hardware} prices and allow software program/licensing fashions, doubtlessly letting Butterfly act extra like a platform provider than a pure gadget vendor. That path is actual, but it surely will depend on ecosystem adoption, scientific validation, and regulatory approvals.

Recent Performance

BFLY has had an enormous 12 months out there — roughly +300% (one-year change) as of mid-July 2026 — comfortably forward of the broader market (S&P 500 1-year complete return ~ +20% space).

The rally traces up with a run of operational and strategic updates throughout late 2025 and 2026: document income in This fall 2025 (and a primary constructive operating-cash-flow quarter), a significant licensing/co-development income contribution from the Midjourney partnership, and the rollout of merchandise and AI instruments (iQ3, Compass AI, and the blind-sweep gestational-age instrument). Investors have additionally paid consideration to the Butterfly Garden/API and the embedded licensing roadmap — collectively, these have helped reframe Butterfly as a platform story with extra recurring and licensing income.

Retail/quant momentum added gas throughout June 2026 quantity spikes.

What’s pushed the outperformance:

(1) execution beats and extra confidence in recurring/licensing income (together with the Midjourney contribution and pipeline),

(2) product/AI regulatory wins plus GovRAMP/TX-RAMP authorizations, which open authorities channels,

(3) enhancing gross-margin tendencies as licensing grows, and

(4) a story shift away from “just a device company” towards a platform/semiconductor angle — the sort of shift that usually expands valuation multiples.

Fundamental Analysis

Growth Prospects

Butterfly remains to be in “prove and scale” mode, however progress has been shifting in the correct path.

Revenue and steering: Butterfly reported FY2025 income of $97.6 million. Q1 2026 income got here in at $26.5 million (+25% YoY), and administration reaffirmed 2026 income steering of $117–$121 million (about ~20–24% progress).

Management is leaning on three progress engines:

• scaling point-of-care,

• commercializing Home & Community Care (with a primary statewide deployment anticipated in Q3 2026), and

• rising Butterfly Embedded licensing/co-development offers, which may deliver each lump-sum and recurring income.

On the info offered, the trailing 12-month gross sales progress ratio is 15.52% versus a market common of ~9.09%. That helps the expansion narrative, although the corporate remains to be small in absolute income phrases relative to the valuation multiples buyers are paying.

What to observe: enterprise adoption of Compass AI, third-party utilization through Butterfly Garden APIs, the timing and scale of HomeCare rollouts, and whether or not extra massive embedded licensing offers present up past Midjourney.

Quality & Moat

This is the place the story remains to be messy — but in addition the place the upside case lives.

Profitability and capital effectivity are at the moment weak: working margin is deeply unfavorable (operating_margin: -77.44%), and ROIC is deeply unfavorable (ROIC: -107.52%). That displays heavy funding and recurring working losses.

There are additionally actual indicators of progress. Gross margins have improved to ~67% in current quarters as licensing income has elevated. And This fall 2025 delivered a constructive working money circulate quarter — a significant milestone for a enterprise making an attempt to show it may flip income into money.

The stability sheet provides it some respiratory room: money & equivalents have been about ~$138 million at March 31, 2026, and market information exhibits a internet money place of roughly ~$118 million. Management has additionally been narrowing losses: Q1 2026 adjusted EBITDA loss improved versus the prior yr.

The moat argument, if it performs out, is Ultrasound‑on‑Chip IP plus an API/developer ecosystem. It’s not computerized — it’s execution-dependent, and sure takes a number of quarters or years to essentially present up within the numbers.

Valuation

On valuation, the market is pricing in a variety of future enchancment.

The offered EV/Sales is 8.66, which is above each its five-year common of 5.27 and the market common of ~4.25. That’s a transparent premium versus historical past and friends.

Forward P/E will not be significant (0.00), as a result of the corporate isn’t anticipated to be GAAP worthwhile within the close to time period.

So what are buyers paying for? Software/licensing progress and margin enlargement. Whether that premium holds up will depend on execution — embedded offers scaling, software program ARR progress, and margins staying sturdy. If income momentum slows or licensing wins don’t scale, the premium can compress. (The offered EV/Sales and 2026 steering are the important thing anchors for judging what the market is implying on progress and margin conversion.)

Market Sentiment

Sentiment has shifted from skeptical to cautiously optimistic.

On the Street, protection is constructive: common worth targets are round $7.06, and consensus is rated “Strong Buy” throughout a small analyst base.

Positioning and flows can swing the inventory round. Short curiosity remains to be significant (stockanalysis exhibits ~10.9% of shares out quick), which may exaggerate strikes when catalysts hit. Retail and momentum participation have been a giant a part of 2026’s worth motion, particularly as social channels pushed the Midjourney and embedded-platform narrative.

Ownership appears blended however notable: institutional possession is reported at ~44.7%, and insiders maintain ~17%.

Overall, sentiment is tilted constructive, but it surely’s fragile — extra depending on headlines and catalysts than on regular, confirmed profitability.

Key Risks

• Execution & focus danger: So far, income has had significant contributions from a small variety of embedded/licensing offers (Midjourney contributed $6.8 million in This fall 2025). If Butterfly doesn’t land extra massive offers — or if HomeCare and enterprise gross sales don’t scale — progress would gradual materially.
• Profitability & capital effectivity: Operating margin is deeply unfavorable (-77.44%) and ROIC is -107.52%. Until working leverage exhibits up and ROIC turns constructive, capital returns stay a serious danger. The offered FCF yield can be unfavorable (-2.53%).
• Valuation & volatility: The inventory is priced at a premium: EV/Sales is 8.66 versus its five-year common of 5.27 and the market at 4.25. It additionally trades with excessive sensitivity and large swings: beta is 2.36, and volatility is 224.61% versus a market common of 34.56%. That combo could make drawdowns sharp when the information circulate turns. (Provided ratios.)
• Competition & regulatory: Incumbent ultrasound distributors can defend share with bundled software program/{hardware} choices. Regulatory setbacks — or slower-than-expected FDA/market clearances for AI instruments — would gradual adoption.
• Balance-sheet & liquidity danger (average): Net debt/EBITDA exhibits 0.00 (the corporate is internet money at present), and money balances of about ~$138 million at 3/31/2026 present runway versus present steering. But if the corporate fails to ship the working leverage administration is aiming for, it may need further financing.

Bull Case

• Platform conversion: Butterfly pulls off the shift from {hardware} vendor to platform/licensing firm. Recurring, high-margin licensing plus a scaled API ecosystem lifts margins and ultimately improves ROIC.
• Accelerating enterprise adoption: Compass AI positive aspects actual enterprise traction, and HomeCare rollouts change into a sturdy recurring income engine. That would increase ARR and enhance income visibility.
• Large embedded contracts: More multi-year embedded/co-development offers land, much like Midjourney. Those can create near-term income jumps and validate the platform thesis.
• Margin enlargement: The income combine retains shifting towards licensing/software program, sustaining gross margin round ~65–70% whereas mounted prices stabilize. That helps a path to constructive adjusted EBITDA and, later, GAAP profitability.
• Significant optionality at a still-small income base: Revenue remains to be below $200 million. If the corporate can sustain 20%+ natural progress and add just a few massive embedded offers, present multiples could make sense — however provided that that progress converts into excessive, recurring margins.

Bear Case

• Narrative wins fail to scale: Midjourney and early API momentum keep one-off or small, and don’t translate into sustained licensing income. That would go away Butterfly leaning on lower-margin {hardware} gross sales once more.
• Margins don’t enhance: Even with larger gross margins, working bills hold the corporate unprofitable. Cash burn may flatten out or rise, forcing dilution or debt financing.
• Valuation re-rating: If progress slows, the excessive EV/Sales premium can compress. At at present’s multiples, that creates actual vulnerability to revenue-taking and a number of contraction.
• Competition & scientific adoption: Hospitals and well being methods stick to incumbents or select different handheld choices. Regulatory delays or weaker scientific outcomes would gradual adoption.
• Event-driven volatility: With excessive quick curiosity and heavy retail/momentum involvement, the inventory can see outsized intraday strikes — and sharp corrections on any unfavorable information.

On Our Radar

• Earnings — Jul 31, 2026: Next estimated earnings launch is Friday, July 31, 2026 (earlier than market open). This ought to replace the Q2 income tempo, software program ARR / embedded pipeline, and any adjustments to 2026 steering.
• Home & Community Care commercialization (Q3 2026): Management expects the primary statewide HomeCare deployment in Q3 2026. Early industrial agreements and preliminary income will likely be key milestones.
• Embedded partnerships / income cadence: Updates on Butterfly Embedded offers — new companions past Midjourney, plus timing and measurement of funds — can transfer near-term income and margins. This fall 2025 disclosed Midjourney commitments of as much as $74 million over 5 years (with $6.8 million acknowledged in This fall 2025).
• Regulatory & product approvals: Watch the rollout of recent AI instruments (together with the blind-sweep gestational-age AI instrument) and any further clearances or authorities contract wins. GovRAMP and TX-RAMP are already achieved, which helps develop entry to authorities channels.

Investment Conclusion

Butterfly is a growth-stage, high-conviction know-how story with a transparent long-term goal: flip Ultrasound‑on‑Chip right into a software program and licensing platform.

The firm is beginning to present proof factors that the combo shift can work: licensing income (together with the Midjourney contribution), enhancing gross margins, and sufficient money to maintain executing whereas it narrows losses (reported money of about ~$138 million at 3/31/2026, and a Q1 2026 adjusted EBITDA loss that narrowed versus the prior yr). But the basics are nonetheless removed from “settled”: ROIC, working margin, and FCF yield are all properly beneath market norms, and the inventory already carries a platform-style premium (EV/Sales above historical past and friends).

Risk ranges are excessive. The inventory’s beta is 2.36 and volatility is 224.61%, so worth swings may be excessive.

For buyers, that is an execution-and-catalyst inventory. The upside will depend on continued enterprise and embedded deal wins, HomeCare commercialization, and scaling software program income profitably. The draw back is significant if these catalysts disappoint or if valuation multiples re-rate decrease.

Long-term buyers who purchase into the platform narrative — and might deal with equity-market volatility — might even see BFLY as one to construct over time round confirmed, repeatable milestones (quarterly licensing/ARR progress and enhancing adjusted EBITDA). More risk-averse buyers could favor to attend for clearer profitability tendencies or a greater valuation cushion. (No express purchase/promote advice is offered.)

| Help us enhance Stock Snapshots — share your feedback.